Compare Invitation Homes Inc. Common Stock (INVH) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invitation Homes Inc. Common Stock vs Viatris Inc — how do they compare? Invitation Homes Inc. Common Stock trades at $26.77 (market cap $15.68B), while Viatris Inc trades at $17.75 (market cap $20.05B). The key difference: Viatris Inc is the larger of the two by market cap, and Invitation Homes Inc. Common Stock pays the higher dividend (4.52%). Which is the better fit depends on your goals — on Pluang, investors hold Invitation Homes Inc. Common Stock for 0 Days and Viatris Inc for 57 Days on average.
| INVH | VTRS | |
|---|---|---|
Market Cap | $15.68B | $20.05B |
Volume | 3,619,685 | 8,682,135 |
Sector | Real Estate | Health |
52-Week High | $30.59 | $18.27 |
52-Week Low | $24.39 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $24.13B | $32.16B |
Dividend Yield | 4.52% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
Viatris (VTRS) trades at $17.25, down 1.65% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue remains stable around $14.3B annually, though the company posted a net loss of $3.51B in 2025. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target, representing 28% upside potential.
The outlook suggests potential upside from current levels if earnings momentum continues, supported by strong cash flow generation and dividend payments. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the generic drug market. The stock appears reasonably valued with P/S of 1.36x, but the elevated P/E of 236x reflects current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
